Adagene Inc. (ADAG)
NASDAQ: ADAG · IEX Real-Time Price · USD
2.540
-0.010 (-0.39%)
Jul 22, 2024, 9:51 AM EDT - Market open
Adagene Employees
Adagene had 174 employees as of December 31, 2023. The number of employees decreased by 74 or -29.84% compared to the previous year.
Employees
174
Change (1Y)
-74
Growth (1Y)
-29.84%
Revenue / Employee
$104,089
Profits / Employee
-$108,887
Market Cap
112.05M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 174 | -74 | -29.84% |
| Dec 31, 2022 | 248 | -11 | -4.25% |
| Dec 31, 2021 | 259 | 61 | 30.81% |
| Dec 31, 2020 | 198 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Augmedix | 1,430 |
| Karyopharm Therapeutics | 325 |
| TELA Bio | 227 |
| I-Mab | 220 |
| RAPT Therapeutics | 131 |
| aTyr Pharma | 59 |
| Elutia | 54 |
| Journey Medical | 41 |
ADAG News
- 10 days ago - Adagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology (ESMO) Congress in September - GlobeNewsWire
- 2 months ago - Adagene to Present at Investor Conferences in June - GlobeNewsWire
- 4 months ago - Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 months ago - Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board - GlobeNewsWire
- 5 months ago - Adagene to Present at the Leerink Partners Global Biopharma Conference 2024 - GlobeNewsWire
- 5 months ago - Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stabl - GlobeNewsWire
- 6 months ago - Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC) - GlobeNewsWire
- 7 months ago - Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium - GlobeNewsWire